Background Concomitant metabolic dysfunction-associated steatotic liver disease (MASLD) is prevalent in patients with chronic ...

Laboratory for Cell-Free Protein Synthesis, RIKEN Center for Biosystems Dynamics Research (BDR), Osaka, Japan Graduate School of Frontier Biosciences, Osaka University, Osaka, Japan Laboratory of ...

Shanghai Qingrun Pharmaceutical Technology Co. Ltd. has discovered new GTPase KRAS mutant inhibitors reported to be useful for the treatment of cancer.

The start-up Function will send practically anyone to a lab for extensive medical testing, no physical required. Is that a good thing? By Kristen V. Brown As Kimberly Crisp approached middle age, ...

Advanced technologies to study protein biophysics, mRNA expression and protein-protein interactions at high throughput in physiological or pathological contexts are reshaping our view of the ARF ...

Endothelial dysfunction, resulting from decreased nitric oxide (NO) bioavailability is a pathology linked to endothelial vasomotor dysfunction and hypertension, inflammation and atherosclerosis, ...

Targeted therapy is the use of agents (typically small molecules, but sometimes monoclonal antibodies, or mAbs) to target cancer cells based on unique biomarkers (typically mutations or other ...

Scientists at the University of California, San Francisco (UCSF), have discovered how to target a class of molecular switches called GTPases that are involved in a myriad of diseases—from Parkinson’s ...

Drp1 (dynamin-related protein 1), a large GTPase, mediates the increased mitochondrial fission, which contributes to hyperproliferation of pulmonary artery smooth muscle cells in pulmonary arterial ...

GTPase KRAS modulators have been described in a recent Quanta Therapeutics Inc. patent and are reported to be useful for the treatment of cancer.